人 KDM3A 抗体对
01AB04072
Lysine demethylase 3A (KDM3A), also known as JMJD1A, is a histone demethylase that specifically targets mono- and dimethylated lysine 9 on histone H3, playing a crucial role in gene expression regulation and transcriptional activation, particularly in hormone-dependent pathways. KDM3A is implicated in various biological processes, including spermatogenesis and metabolic regulation, contributing to obesity resistance by modulating genes such as PPARα and UCP1. Dysregulation of KDM3A has been associated with several diseases, notably cancer; it facilitates chemoresistance and cancer stemness by demethylating key proteins like p53, thereby inhibiting apoptotic pathways. Additionally, KDM3A's overexpression is linked to prostate cancer progression through its interaction with androgen receptors and hypoxia-inducible factors, making it a potential therapeutic target for cancer treatment.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- KDM3A
- 基因别名
- JHDM2A; JMJD1; JMJD1A; KIAA0742; TSGA
- 蛋白别名
- lysine demethylase 3A; KDM3A
- UniProt
- Q9Y4C1
- 物种
- Human
产品详情
- 靶点名称
- KDM3A
- 蛋白名称
- lysine demethylase 3A
- 蛋白别名
- Lysine-specific demethylase 3A; JmjC domain-containing histone demethylation protein 2A; Jumonji domain-containing protein 1A; [histone H3]-dimethyl-L-lysine(9) demethylase 3A
- 靶点基因名
- KDM3A
- 基因别名
- JHDM2A; JMJD1; JMJD1A; KIAA0742; TSGA
- UniProt
- Q9Y4C1
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Lysine demethylase 3A (KDM3A), also known as JMJD1A, is a histone demethylase that specifically targets mono- and dimethylated lysine 9 on histone H3, playing a crucial role in gene expression regulation and transcriptional activation, particularly in hormone-dependent pathways. KDM3A is implicated in various biological processes, including spermatogenesis and metabolic regulation, contributing to obesity resistance by modulating genes such as PPARα and UCP1. Dysregulation of KDM3A has been associated with several diseases, notably cancer; it facilitates chemoresistance and cancer stemness by demethylating key proteins like p53, thereby inhibiting apoptotic pathways. Additionally, KDM3A's overexpression is linked to prostate cancer progression through its interaction with androgen receptors and hypoxia-inducible factors, making it a potential therapeutic target for cancer treatment.